- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rahway Today
By the People, for the People
Merck Initiates Pivotal Trial for Investigational Tie2 Agonist/VEGF Inhibitor
The Phase 2b/3 trial will evaluate MK-8748 (Tiespectus) for the treatment of neovascular age-related macular degeneration.
Apr. 2, 2026 at 3:26pm
Got story updates? Submit your updates here. ›
Merck has announced the initiation of a pivotal Phase 2b/3 clinical trial evaluating MK-8748, also known as Tiespectus, a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF) for the treatment of neovascular age-related macular degeneration.
Why it matters
Despite available therapies, many patients with neovascular age-related macular degeneration remain at risk of further vision loss due to continued vascular leakage. This new investigational treatment aims to address this unmet need by targeting both the Tie2 pathway and VEGF inhibition.
The details
The pivotal trial will evaluate the safety and efficacy of MK-8748 (Tiespectus) in patients with neovascular age-related macular degeneration. Merck's novel bispecific antibody is designed to directly activate the Tie2 signaling pathway, which plays a key role in maintaining vascular stability, while also inhibiting VEGF to reduce vascular leakage.
- Merck announced the initiation of the pivotal Phase 2b/3 trial on April 2, 2026.
The players
Merck
A global healthcare company that develops and provides innovative medicines, vaccines, biologic therapies, and animal health products.
MK-8748 (Tiespectus)
Merck's novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF) for the treatment of neovascular age-related macular degeneration.
What’s next
Merck will continue to enroll patients and conduct the pivotal Phase 2b/3 clinical trial to evaluate the safety and efficacy of MK-8748 (Tiespectus) for the treatment of neovascular age-related macular degeneration.
The takeaway
This new investigational treatment from Merck represents a potential advancement in addressing the unmet need for patients with neovascular age-related macular degeneration who continue to experience vision loss despite available therapies. The initiation of this pivotal trial is an important step forward in the development of this novel bispecific antibody approach.
